Longitudinal non-interventional observational study on Adherence, safety and tolerability of AVANZ® in adults and GRAZAX® and SLIToneULTRA® in adults and children (5 – 17 years) in patients with allergic Rhinoconjunctivitis in GErmany

Longitudinal non-interventional observational study on Adherence, safety and tolerability of AVANZ® in adults and GRAZAX® and SLIToneULTRA® in adults and children (5 – 17 years) in patients with allergic Rhinoconjunctivitis in GErmany - LARGE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005069

Enrollment

1500

Registered

2013-07-04

Start date

2013-06-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J30.1 J30.3

Interventions

Group 1: Routine treatment with specific immunotherapy (AVANZ® or GRAZAX® or SLIToneULTRA®)

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Routine treatment with specific immunotherapy (AVANZ®/GRAZAX®/SLIToneULTRA®)

Exclusion criteria

Exclusion criteria: Contraindications of specific immunotherapy

Design outcomes

Primary

Measure	Time frame
Adherence / persistence during the planned 3-year course of specific immunotherapy quantified by the proportion of completers considering treatment discontinuations due to adverse events or reasons definitely not related to treatment, frequency of re-prescriptions.	—

Secondary

Measure	Time frame
Safety and tolerability during the planned 3-year course of treatment, application of measures to increase compliance, predictive factors for adherence/persistence, correlation with therapeutic effect, patient questionnaire for health care research	—

Countries

Germany

Contacts

Public ContactHendrik Wolf

ALK-Abelló Arzneimittel GmbH, Clinical Development

hendrik.wolf@alk.net+49 40 703845-342

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026